The five-year-old girl, known only as Maja, is battling acute lymphoblastic leukaemia. She visited a local tattoo parlour in Cleveland, Ohio, where she was shown all the tools.
ConclusionsBBz CAR-T showed similar antitumor activity, but a more favorable safety profile, compared with 28z CAR-T. This study proved the competence of BBz CAR-T in B-NHL therapy, at least under our manufacturing process.Legal entity responsible for the studyPeking University Cancer Hospital&Institute.FundingImmunochina Pharmaceuticals Co., Ltd.DisclosureAll authors have declared no conflicts of interest.
CONCLUSIONS: Our data indicates that ARID5B is an important molecular determinant of antimetabolite drug sensitivity in ALL, in part through p21-mediated effects on cell-cycle progression.
PMID: 31573954 [PubMed – as supplied by publisher]
Arora SK, Swarnim S, Hemal A, Bidhuri N. Acute lymphoblastic leukemia presenting as nephromegaly in a child: A rare case report. Turk J Pediatr 2019; 61: 97-101. Acute leukemia is the commonest pediatric malignancy with acute lymphoblastic leukemia (ALL) constituting about 75% of all leukemias. ALL commonly presents as fever, bleeding, bone pains, anemia, lymphadenopathy and hepatosplenomegaly. The liver, spleen or lymph nodes are the most common sites of extramedullary involvement in ALL, with renal involvement being relatively uncommon. The usual differential diagnosis of acquired massive bilateral neph…
This study aimed to analyze the role of postoperative treatment for BC in the development of subsequent HM. Using the French National Health Data System, we examined the HM risks in patients diagnosed with an incident primary breast cancer between 2007 and 2015, who underwent surgery as first-line treatment for BC. Main outcomes were acute myeloid leukemia (AML), Myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), multiple myeloma (MM), Hodgkin’s lymphoma or non-Hodgkin’s lymphoma (HL/NHL), and acute lymphoblastic leukemia or lymphocytic lymphoma (ALL/LL). Analyses were censored at HM o…
Authors: Aisyi M, Andriastuti M, Kurniati N
BACKGROUND: Hyperglycaemia is a common side effect of steroid and L-asparaginase combinations, occurring mostoften during acute lymphoblastic leukemia (ALL) induction phase. To date in Indonesia, it has not been obtained dataon the incidence of hyperglycemia in children with ALL in the induction phase and how the role of combinations ofL-asparaginase and different type of steroid used. The purpose of this study is to determine the incidence of hyperglycemiain children ALL induction phase, knowing the difference between prednisone and dexamethasone (in combination…
This study demonstrated that GLN was capable to extend chemotherapeutic sensitivity in ALL cells by reducing VCR concentration without constraining its effectiveness. Therefore, it might act as a promising anticancer agent for the treatment of leukemia.
PMID: 31544515 [PubMed – as supplied by publisher]
CONCLUSION: miR-146a could promote the proliferation, migration, and invasion and inhibit the apoptosis of AL Jurkat and HL-60 cells by downregulating CNTFR and activating the JAK2/STAT3 pathway.
PMID: 31538427 [PubMed – in process]
Conclusion: This case demonstrates the importance of a broad differential diagnosis for a child presenting with leg pain and fever.
PMID: 31528139 [PubMed]
The extraordinary and unexpected success of cellular immunotherapy using genetically engineered T-cells to express a chimeric antigen receptor (CAR) targeting CD19, in the treatment of refractory or relapsing B-hematological malignancies, has provided a real therapeutic hope. Indeed, remission rates reach more than 80 % in patients at a stage, without any other possibilities of treatment, notably in the child’s acute lymphoblastic leukemia. These results, initially resulting from academic research, led to Food and Drug accreditation for market access of two innovative autologous therapy drugs, …
A promising and expensive type of immunotherapy, called CAR T-cell therapy, is now covered by Medicare.
This news may affect mesothelioma patients in the future.
Chimeric antigen receptor T-cell, or CAR T-cell, therapy involves the laboratory reprogramming of a patient’s T cells, which are a type of white blood cell responsible for protecting the body against infection and disease. The T cells are genetically modified to better recognize and attack cancer.
The U.S. Food and Drug Administration has approved the immunotherapy procedure for non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia. It is…